Alaunos Therapeutics (TCRT) Enterprise Value (2016 - 2025)
Alaunos Therapeutics (TCRT) has disclosed Enterprise Value for 15 consecutive years, with -$1.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 15.15% year-over-year to -$1.9 million, compared with a TTM value of -$1.9 million through Sep 2025, down 15.15%, and an annual FY2024 reading of -$1.1 million, up 82.0% over the prior year.
- Enterprise Value was -$1.9 million for Q3 2025 at Alaunos Therapeutics, up from -$2.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$319000.0 in Q1 2025 and bottomed at -$100.1 million in Q1 2021.
- Average Enterprise Value over 5 years is -$35.0 million, with a median of -$18.3 million recorded in 2023.
- Peak annual rise in Enterprise Value hit 92.3% in 2025, while the deepest fall reached 16.89% in 2025.
- Year by year, Enterprise Value stood at -$76.1 million in 2021, then surged by 30.32% to -$53.0 million in 2022, then skyrocketed by 88.56% to -$6.1 million in 2023, then skyrocketed by 82.0% to -$1.1 million in 2024, then tumbled by 77.64% to -$1.9 million in 2025.
- Business Quant data shows Enterprise Value for TCRT at -$1.9 million in Q3 2025, -$2.9 million in Q2 2025, and -$319000.0 in Q1 2025.